Safety monitoring for people taking Leqembi for Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This study tracks the safety of Leqembi (lecanemab), a treatment for Alzheimer's disease, in people who are already prescribed it in the UK. It helps doctors learn more about how the medicine affects patients in everyday life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are taking or have been prescribed Leqembi (lecanemab).
- You are enrolled in the controlled access programme for Leqembi.
- You have not taken any other anti-amyloid antibody treatments before (like aducanumab).
- You are not currently in another clinical trial for mild cognitive impairment or Alzheimer's disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study observes people with Alzheimer's disease who are taking leqembi in Taiwan to learn more about how it works in everyday use. It may help understand the treatment's benefits and risks outside of clinical trials.
This study follows people with Alzheimer's who are already taking Leqembi (lecanemab) after being in the JOY-ALZ study. It collects medical information to check how the treatment works in real-world use.
This study looks at the long-term effects of the Alzheimer's drug LEQEMBI (lecanemab) in people with mild memory problems or early Alzheimer's. It gathers information from patients who have already been taking the drug for 18 months to see how they are doing.
This study tests a new treatment, called X/T, for people with Alzheimer's disease who are already taking lecanemab (Leqembi). The goal is to see if adding X/T is safe and tolerable, and if it might help manage symptoms.
This study collects information from people in Canada who have Alzheimer's disease and are prescribed the drug lecanemab (LEQEMBI). It helps doctors learn more about the drug's safety and effects in real-world use.
This study tracks the real-world experience of people with early Alzheimer's disease who are already taking lecanemab. It aims to better understand how the medication works and its safety in everyday medical practice.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.